XC8 in the Treatment of Patients With Acute Respiratory Viral Infection
Status:
Completed
Trial end date:
2017-02-09
Target enrollment:
Participant gender:
Summary
A multicenter double-blind, randomized, placebo-controlled, parallel-group comparative Phase
II / III clinical study to assess safety, tolerability, efficacy and optimal dose ranging of
XC8 vs. placebo in patients with uncomplicated influenza or other ARVI during a 5-day
treatment.
The primary objective of the study was to demonstrate the difference in time before the onset
of a sustained improvement in clinical symptoms according to the Severity Rating Scale for
ARVI, and to determine the optimal dose of XC8 in the treatment of influenza and other ARVI.